MarketCap
Facebook
X
TelegramQuarterly report 2023-Q4
added 02-12-2024
Nemaura Medical Cost of Revenue 2011-2026 | NMRD
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Nemaura Medical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 75.3 K | 344 K | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 344 K | 75.3 K | 210 K |
Quarterly Cost of Revenue Nemaura Medical
| 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 2.97 K | 72.4 K | 72.4 K | - | 172 K | 172 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 172 K | 2.97 K | 98.5 K |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aethlon Medical
AEMD
|
3.87 M | $ 2.11 | 8.21 % | $ 3.29 M |  USA |
 |
AdaptHealth Corp.
AHCO
|
2.64 B | $ 10.42 | -1.65 % | $ 1.41 B | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
Acutus Medical
AFIB
|
10.3 M | - | -26.83 % | $ 2.62 M | USA |
 |
Alphatec Holdings
ATEC
|
232 M | $ 12.6 | 2.61 % | $ 1.89 B | USA |
 |
Butterfly Network
BFLY
|
33.2 M | $ 3.91 | 2.62 % | $ 828 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
104 M | $ 8.38 | -0.24 % | $ 602 M |  Israel |
 |
Aziyo Biologics
AZYO
|
5.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
Boston Scientific Corporation
BSX
|
6.22 B | $ 69.79 | 0.95 % | $ 103 B | USA |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
EDAP TMS S.A.
EDAP
|
37.6 M | $ 3.96 | 1.02 % | $ 148 M |  France |
 |
CONMED Corporation
CNMD
|
624 M | $ 37.41 | 0.35 % | $ 1.16 B | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
Cytosorbents Corporation
CTSO
|
10.5 M | $ 0.65 | -8.13 % | $ 35.4 M | USA |
 |
Cutera
CUTR
|
171 M | - | -10.19 % | $ 1.99 M | USA |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
ClearPoint Neuro
CLPT
|
12.3 M | $ 11.03 | 2.22 % | $ 298 M | USA |
 |
Establishment Labs Holdings
ESTA
|
64.8 M | $ 63.48 | 0.21 % | $ 1.88 B |  Costa-rica |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
InMode Ltd.
INMD
|
79.5 M | $ 13.43 | -0.81 % | $ 868 M | Israel |
 |
GBS
GBS
|
1.81 M | - | -0.57 % | $ 7.12 M | USA |
 |
Abbott Laboratories
ABT
|
19.3 B | $ 109.95 | 1.8 % | $ 191 B | USA |
 |
Delcath Systems
DCTH
|
11.8 M | $ 9.81 | 3.81 % | $ 351 M | USA |
 |
Bio-Rad Laboratories
BIO
|
1.19 B | $ 261.24 | -0.59 % | $ 7.37 B | USA |
 |
Helius Medical Technologies
HSDT
|
583 K | $ 2.19 | 3.79 % | $ 1.33 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
728 M | $ 9.01 | -2.49 % | $ 694 M | USA |
 |
AxoGen
AXGN
|
57.9 M | $ 32.84 | 1.55 % | $ 1.51 B | USA |
 |
Align Technology
ALGN
|
1.2 B | $ 169.45 | 3.18 % | $ 12.7 B | USA |
 |
Bruker Corporation
BRKR
|
1.72 B | $ 32.76 | -2.93 % | $ 4.88 K | USA |
 |
IRIDEX Corporation
IRIX
|
30.1 M | $ 1.33 | 2.31 % | $ 21.5 M | USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
Apyx Medical Corporation
APYX
|
19.8 M | $ 3.67 | 1.1 % | $ 151 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
63.7 M | $ 17.11 | -1.16 % | $ 401 M | USA |
 |
Integer Holdings Corporation
ITGR
|
1.35 B | $ 84.12 | 1.34 % | $ 2.92 B | USA |
 |
Invacare Corporation
IVC
|
566 M | - | - | $ 24.7 M | USA |
 |
Second Sight Medical Products
EYES
|
11.8 M | - | -0.97 % | $ 54.4 M | USA |